Results 11 to 20 of about 22,351 (243)

The impact of fingolimod on Treg function in brain ischaemia

European Journal of Immunology, 2023
Fingolimod has generally shown neuroprotective effects in stroke models. Here, we tested the hypothesis that fingolimod modulates T-cell cytokine production towards a regulatory phenotype.
Waeber, Christian, Kyle Malone, Anne C. Moore, Malone, Kyle, Christian Waeber, Shearer, Jennifer A., Jennifer A. Shearer, Moore, Anne C.   +7 more
core   +2 more sources

Multiple Sclerosis Relapses Following Cessation of Fingolimod

Clinical drug investigation, 2022
BACKGROUND: There is growing interest in the issue of disease reactivation in multiple sclerosis following fingolimod cessation. Relatively little is known about modifiers of the risk of post-cessation relapse, including the delay to commencement of new ...
Hodgkinson, S, Alroughani, R, Izquierdo, G, Eichau, Sara, Skibina, Olga, Patti, F, Malpas, Charles B, Horakova, D, Roos, I, Malpas, CB, Izquierdo, Guillermo, Lechner-Scott, J, Sharmin, Sifat, Lechner-Scott, Jeannette, Butzkueven, Helmut, Patti, Francesco, Sharmin, S, Skibina, O, Alroughani, Raed, Butzkueven, H, Havrdova, EK, Hodgkinson, Suzanne, Buzzard, K, Kappos, Ludwig, Grammond, P, Havrdova, Eva Kubala, Buzzard, Katherine, MSBase Study Group, Kalincik, T, Roos, Izanne, Grammond, Pierre, Kappos, L, Kalincik, Tomas, Eichau, S, Horakova, Dana   +34 more
core   +2 more sources

Modulation of Cardiac Autonomic Function by Fingolimod Initiation and Predictors for Fingolimod Induced Bradycardia in Patients with Multiple Sclerosis

Frontiers in Neuroscience, 2017
Objective: It is well-known that initiation of fingolimod induces a transient decrease of heart rate. However, the underlying cardiac autonomic regulation is poorly understood. We aimed to investigate the changes of autonomic activity caused by the first
Kai Li, Kai Li, Urszula Konofalska, Katja Akgün, Manja Reimann, Heinz Rüdiger, Rocco Haase, Tjalf Ziemssen, Tjalf Ziemssen   +8 more
doaj   +2 more sources

Fingolimod attenuates experimental autoimmune neuritis and contributes to Schwann cell-mediated axonal protection [PDF]

Journal of Neuroinflammation, 2017
Background Fingolimod, a sphingosine-1-phosphate receptor modulator with well-described immunomodulatory properties involving peripheral immune cell trafficking, was the first oral agent approved for the treatment of relapsing remitting multiple ...
Björn Ambrosius, Kalliopi Pitarokoili, Lisa Schrewe, Xiomara Pedreiturria, Jeremias Motte, Ralf Gold   +5 more
doaj   +2 more sources

Initiating oral fingolimod treatment in patients with multiple sclerosis

Therapeutic Advances in Neurological Disorders, 2013
Fingolimod, the first oral disease-modifying therapy (DMT) approved for the treatment of multiple sclerosis (MS) and the only sphingosine 1-phosphate receptor modulator approved for any disease state, represents an important addition to the expanding DMT
Barry A. Singer
doaj   +2 more sources

Fingolimod for multiple sclerosis and emerging indications: appropriate patient selection, safety precautions, and special considerations

Therapeutics and Clinical Risk Management, 2016
Ilya Ayzenberg, Robert Hoepner, Ingo Kleiter Department of Neurology, St Josef Hospital, Ruhr University Bochum, Bochum, Germany Abstract: Fingolimod (FTY720), an immunotherapeutic drug targeting the sphingosine-1-phosphate receptor, is a widely used ...
Ayzenberg I, Hoepner R, Kleiter I
doaj   +1 more source

Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis.

JAMA Neurology, 2023
Importance Autologous hematopoietic stem cell transplant (AHSCT) is available for treatment of highly active multiple sclerosis (MS). Objective To compare the effectiveness of AHSCT vs fingolimod, natalizumab, and ocrelizumab in relapsing-remitting MS ...
T. Kalincik, S. Sharmin, I. Roos, M. Freedman, H. Atkins, J. Burman, J. Massey, I. Sutton, Barbara Withers, Richard Macdonell, A. Grigg, Øivind Torkildsen, L. Bø, A. K. Lehmann, E. Havrdová, E. Krasulová, M. Trněný, T. Kozák, A. van der Walt, H. Butzkueven, P. Mccombe, O. Skibina, J. Lechner-Scott, B. Willekens, E. Cartechini, S. Ozakbas, R. Alroughani, J. Kuhle, F. Patti, P. Duquette, A. Lugaresi, S. Khoury, M. Slee, R. Turkoglu, S. Hodgkinson, N. John, D. Maimone, M. Sá, V. van Pesch, O. Gerlach, G. Laureys, Liesbeth Van Hijfte, R. Karabudak, D. Spitaleri, T. Csépány, R. Gouider, T. Castillo-Triviño, B. Taylor, B. Sharrack, J. Snowden, S. Mrabet, J. Garber, J. Sánchez-Menoyo, E. Aguera-Morales, Y. Blanco, A. Al-Asmi, B. Weinstock-Guttman, Y. Fragoso, K. de Gans, A. Kermode   +59 more
semanticscholar   +1 more source

Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies.

JAMA Neurology, 2020
Importance Although highly effective disease-modifying therapies for multiple sclerosis (MS) have been associated with an increased risk of infections vs injectable therapies interferon beta and glatiramer acetate (GA), the magnitude of potential risk ...
G. Luna, Peter Alping, J. Burman, K. Fink, A. Fogdell-Hahn, M. Gunnarsson, J. Hillert, A. Langer-Gould, J. Lycke, P. Nilsson, J. Salzer, A. Svenningsson, M. Vrethem, T. Olsson, F. Piehl, T. Frisell   +15 more
semanticscholar   +1 more source

Comparison Between Dimethyl Fumarate, Fingolimod, and Ocrelizumab After Natalizumab Cessation.

JAMA Neurology, 2023
Importance Natalizumab cessation is associated with a risk of rebound disease activity. It is important to identify the optimal switch disease-modifying therapy strategy after natalizumab to limit the risk of severe relapses.
Chao Zhu, T. Kalincik, D. Horáková, Zhen Zhou, K. Buzzard, O. Skibina, R. Alroughani, Guillermo Izquierdo, S. Eichau, J. Kuhle, F. Patti, F. Grand'Maison, S. Hodgkinson, P. Grammond, J. Lechner-Scott, E. Butler, A. Prat, M. Girard, P. Duquette, R. Macdonell, B. Weinstock-Guttman, S. Ozakbas, M. Slee, M. Sá, V. van Pesch, M. Barnett, B. Van Wijmeersch, O. Gerlach, J. Prevost, M. Terzi, C. Boz, G. Laureys, Liesbeth Van Hijfte, A. Kermode, J. Garber, B. Yamout, S. Khoury, Daniele Merlo, M. Monif, V. Jokubaitis, A. van der Walt, H. Butzkueven   +41 more
semanticscholar   +1 more source

Neuroprotective Effects of Fingolimod Supplement on the Retina and Optic Nerve in the Mouse Model of Experimental Autoimmune Encephalomyelitis

Frontiers in Neuroscience, 2021
Favorable effects exerted by long-term administration of fingolimod therapy in multiple sclerosis (MS) patients have been reported, but sporadic side effects, such as reversible macular edema, also have been recorded. The present study aimed to determine
Tao Yang, Zheng Zha, Xiao Yang, YueZhi Kang, Xin Wang, Yanping Tong, XueSong Zhao, Lei Wang, YongPing Fan   +8 more
doaj   +1 more source